Category: General

Is The Market Waiting Until Next Week To Make A Move?

Posted on by The INO.com Team

Hello MarketClub members everywhere. Next week, Amazon.com (NASDAQ:AMZN), Apple Inc. (NASDAQ:AAPL) And Alphabet Inc. (NASDAQ:GOOG) all report earnings. This could be the catalyst to get the market out of the doldrums and the sideways pattern that I've been talking about for what seems like ever.

Yesterday Microsoft Corporation (NASDAQ:MSFT) announced its earnings a beat 76 cents vs. 68 estimates, that was enough to push the stock up above its 1999 highs of $59.97 in after-her-hour ours trading. It would appear that the turnaround efforts for Microsoft are on track under the guidance of Microsoft's CEO Satya Nadella.

The market has been remarkably quiet with most of the noise coming out of the presidential campaign this week.

Once again, MarketClub's Trade Triangles point the way to successful trading. If you are not tracking the Trade Triangles, you may decide to do so after looking at how they are positioned in many of the markets.

Looking at the major markets here are the minuscule changes so far this week (Thursday Closes). Continue reading "Is The Market Waiting Until Next Week To Make A Move?" →

The Aftermath Of Brexit Has Created A Buying Opportunity

Posted on by The INO.com Team

By: Joseph Hogue of Street Authority

Geopolitical issues have dominated the markets this year, and polls have been useless in lending any kind of certainty to asset prices.

OPEC has successfully managed expectations for a production freeze, even if an eventual deal is still unlikely, which has driven oil prices to nearly double since their February lows. Few would have predicted in January the momentum of the Trump campaign and the potential uncertainty on global trade.

As important as these events have been, however, 2016 will likely be remembered for one event in particular. Continue reading "The Aftermath Of Brexit Has Created A Buying Opportunity" →

Weekly Futures Recap With Mike Seery

Posted on by The INO.com Team

We've asked Michael Seery of SEERYFUTURES.COM to give our INO readers a weekly recap of the Futures market. He has been Senior Analyst for close to 15 years and has extensive knowledge of all of the commodity and option markets.

Michael frequently appears on multiple business networks including Bloomberg news, Fox Business, CNBC Worldwide, CNN Business, and Bloomberg TV. He is also a guest on First Business, which is a national and internationally syndicated business show.

Cotton Futures

Cotton futures in the December contract is now trading above its 20 and 100-day moving average for the first time since last summer as prices spiked higher off of the USDA crop report stating that ending stocks currently stand at 4.3 million bales and that is down 12% from the September report sending prices to a 2 week high. At present, I’m sitting on the sidelines in this market as there is no trend, but it does look to me that a possible bottom has been created as prices settled last Friday in New York at 66.98. It's currently trading at 69.65 up about 300 points for the trading week despite the fact that the U.S dollar has now hit an 8 month high and a 31 year high against the British Pound which is generally a negative influence on commodity prices. Harvest is in full swing in the southern part of the United States as there were concerns about Hurricane Matthew potentially damaging yields as the next report will state if that situation is true. Continue reading "Weekly Futures Recap With Mike Seery" →

Preview Issue #4 - Mylan Capitulates, M&A Activity Heats Up and the Negative Political Backdrop

Posted on by Noah Kiedrowski

INO Health & Biotech Stock Guide

Preview Issue #3 - October 13th, 2016

BIOTECH, HEALTH & PHARMA NEWS

Mylan has been a whipping post as of late over its aggressive pricing increases regarding its EpiPen which uses an auto-injection of epinephrine to treat severe allergic reactions in primarily school age children. As a result, Mylan has ostensibly capitulated in the face of public and governmental scrutiny regarding its EpiPen pricing with implementing plans to offer a generic version and a $465 million settlement with the U.S. department of Justice to appease the public and improve its company image. The relentless congressional grilling on Capitol Hill and public backlash against Mylan and its CEO looks to have spurred the company into offering a generic and cheaper version of its EpiPen as well as providing more EpiPen via its access programs. However, congressional leaders continue to criticize Mylan over its alleged misrepresentation of profits and under paying Medicare in rebates. Congressional leaders stated that Mylan was dishonest when it incorrectly applied a statutory U.S. tax rate on its EpiPen revenue. The company is technically based ex-U.S. and thus pays a lower tax rate. Furthermore, the company has been accused of misclassifying the EpiPen to game the Medicaid Drug Rebate Program. Mylan has been reportedly paying a 13% rebate that is reserved for generics while the brand name EpiPen should be at a minimum of a 21% rebate rate. Congressional leaders have vowed to recoup the difference over the past five years Medicaid has spent on EpiPens (total Medicaid spending from 2011 through 2015 was reported to be $960 million for the EpiPen). To this end, Mylan just settled a $465 million lawsuit regarding this egregious misclassification under the Medicaid Drug Rebate Program. This negative publicity along with continuous political attacks has been a major overhang impacting biotech stocks. This public and contentious battle with government officials and the general public doesn’t bode well for the entire healthcare cohort. With ongoing presidential debates and political posturing still occurring, this will likely continue to be a source of volatility. Buying opportunities may present themselves throughout the sector due to extraneous political rhetoric regarding the drug pricing debate and the entire drug supply chain dynamics.

WHAT'S NEXT

Continue reading "Preview Issue #4 - Mylan Capitulates, M&A Activity Heats Up and the Negative Political Backdrop" →

Weekly Futures Recap With Mike Seery

Posted on by The INO.com Team

We've asked Michael Seery of SEERYFUTURES.COM to give our INO readers a weekly recap of the Futures market. He has been Senior Analyst for close to 15 years and has extensive knowledge of all of the commodity and option markets.

Michael frequently appears on multiple business networks including Bloomberg news, Fox Business, CNBC Worldwide, CNN Business, and Bloomberg TV. He is also a guest on First Business, which is a national and internationally syndicated business show.

Gold Futures

Gold futures in the December contract settled last Friday in New York at 1,317 while currently trading at 1,256 down about $60 for the trading week hitting a 4 month low all due to the fact that the U.S dollar is hitting a 31 year low against the British Pound pushing prices lower. Gold is trading below its 20 and 100-day moving average telling you that the short-term trend clearly is to the downside as prices are retesting the Brexit low which happened in late June with the next major level of resistance is between 1,200/1,220 in my opinion. At the current time, I’m not involved in gold or silver, but I’m not recommending any type of bullish scenario as I do think lower prices are ahead as I do not like to counter trend trade as over the course time that is very dangerous. Continue reading "Weekly Futures Recap With Mike Seery" →